HTA Council Recommendation (as of 26 November 2024) The HTA Council positively recommends Abacavir + Lamivudine [120 mg / 60 mg dispersible tablet] for the treatment of human immunodeficiency virus (HIV) infection in pediatric population for the inclusion in the PNF and thus the government financing of the said health technology. Relevant Information Evidence and continue reading : Abacavir + Lamivudine [120 mg / 60 mg dispersible tablet] for the treatment of human immunodeficiency virus (HIV) infection in pediatric population
Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y
HTA Council Recommendation (as of 10 February 2026) As a final recommendation, the HTA Council recommends the government financing of the Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for individuals from the age of 6 weeks (pediatric population) and populations at high-risk for invasive diseases*, with priority for: *population at high-risk for continue reading : Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y
Moderate Complexity Nucleic Acid Amplification Tests (NAATS) for the diagnosis of Multi-drug Resistant Tuberculosis (MDR-TB) with isoniazid (INH) and rifampicin (RIF) resistance testing
HTA Council Recommendation (as of 01 December 2025) As a final recommendation, the HTA Council recommends moderate complexity NAATs for the diagnosis of MDR-TB with INH and RIF resistance testing, for financing of DOH and/or PhilHealth. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Chip-based RT-PCR MTB-RIF test for screening or diagnosis of multidrug-resistant tuberculosis (MDR-TB)
HTA Council Recommendation (as of 9 July 2025) The HTA Council positively recommends the government financing of Chip-based RT-PCR MTB-RIF test for screening or diagnosis of multidrug-resistant tuberculosis (MDR-TB) The HTA Council recommends that the Department of Health refer to existing and future WHO target product profiles (TPPs) when selecting tests for procurement. In the continue reading : Chip-based RT-PCR MTB-RIF test for screening or diagnosis of multidrug-resistant tuberculosis (MDR-TB)
HIV/Syphilis Duo Test for screening of HIV and Syphilis infection in pregnant women as part of antenatal care, ideally during the first trimester
HTA Council Recommendation (as of 18 June 2025) The HTA Council positively recommends the government financing of HIV/Syphilis Duo Test for screening of HIV and Syphilis infection in pregnant women as part of antenatal care, ideally during the first trimester The HTA Council strongly recommends that implementation of HIV health technologies should follow the WHO continue reading : HIV/Syphilis Duo Test for screening of HIV and Syphilis infection in pregnant women as part of antenatal care, ideally during the first trimester